Columbia Care, LLC announced on June 21st the company’s entrance into a license agreement with Rhinomed (ASX: RNO) to develop a cannabis product line where the products will be delivered through nasal passageways.

Rhinomed is an Australian-based company that specifically works with nasal respiratory products. However, Columbia Care will keep the exclusive rights to develop, import, market, promote, distribute, and sell the product, which the two companies will collaborate in creating, in the United States.

According to the terms of the agreement the two companies will collaborate on the development of one or multiple versions of a nasal cannabis product. This product will be developed in Columbia Care’s facilities and will utilize Columbia Care’s pharmaceutical-grade cannabis medicines.

Leave a Reply